Moraxella-dominated pediatric nasopharyngeal microbiota associate with upper respiratory infection and sinusitis

Distinct bacterial upper airway microbiota structures have been described in pediatric populations, and relate to risk of respiratory viral infection and, exacerbations of asthma. We hypothesized that distinct nasopharyngeal (NP) microbiota structures exist in pediatric populations, relate to enviro...

Full description

Saved in:
Bibliographic Details
Published in:PloS one Vol. 16; no. 12; p. e0261179
Main Authors: McCauley, Kathryn E, DeMuri, Gregory, Lynch, Kole, Fadrosh, Douglas W, Santee, Clark, Nagalingam, Nabeetha N, Wald, Ellen R, Lynch, Susan V
Format: Journal Article
Language:English
Published: United States Public Library of Science 28-12-2021
Public Library of Science (PLoS)
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Distinct bacterial upper airway microbiota structures have been described in pediatric populations, and relate to risk of respiratory viral infection and, exacerbations of asthma. We hypothesized that distinct nasopharyngeal (NP) microbiota structures exist in pediatric populations, relate to environmental exposures and modify risk of acute sinusitis or upper respiratory infection (URI) in children. Bacterial 16S rRNA profiles from nasopharyngeal swabs (n = 354) collected longitudinally over a one-year period from 58 children, aged four to seven years, were analyzed and correlated with environmental variables, URI, and sinusitis outcomes. Variance in nasopharyngeal microbiota composition significantly related to clinical outcomes, participant characteristics and environmental exposures including dominant bacterial genus, season, daycare attendance and tobacco exposure. Four distinct nasopharyngeal microbiota structures (Cluster I-IV) were evident and differed with respect to URI and sinusitis outcomes. These clusters were characteristically either dominated by Moraxella with sparse underlying taxa (Cluster I), comprised of a non-dominated, diverse microbiota (Cluster II), dominated by Alloiococcus/Corynebacterium (Cluster III), or by Haemophilus (Cluster IV). Cluster I was associated with increased risk of URI and sinusitis (RR = 1.18, p = 0.046; RR = 1.25, p = 0.009, respectively) in the population studied. In a pediatric population, URI and sinusitis associate with the presence of Moraxella-dominated NP microbiota.
Bibliography:Competing Interests: S.V. Lynch is a board member and reports personal consulting fees from Siolta Therapeutics outside the submitted work; has a patent “Reductive prodrug cancer chemotherapy (Stan449-PRV)" issued, a patent “Combination antibiotic and antibody therapy for the treatment of Pseudomonas aeruginosa infection (WO2010091189A1)" with royalties paid by KaloBios, a patent “Therapeutic microbial consortium” and “Methods and Compositions Relating to Epoxide Hydrolase genes” licensed to Siolta Therapeutics Inc., a patent “Systems and methods for detecting antibiotic resistance (WO2012027302A3)" issued, a patent “Nitroreductase enzymes (US7687474B2)" issued, a patent “Sinusitis diagnostics and treatments (WO2013155370A1)" licensed by Reflourish, and a patent “Methods and systems for phylogenetic analysis (US20120264637A1)" issued. This does not alter our adherence to PLOS ONE policies on sharing data and materials. All other authors declare no relevant conflicts of interest.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0261179